Merck Reports Q3 2026 Results with $18.1 Billion in Sales and Raised Full-Year Guidance
Merck (MRK) reported third-quarter sales of $18.1 billion, a 5% year-over-year increase driven by strong performance in oncology and animal health. Key growth drivers included Keytruda/QLEX sales at $8.6 billion and a significant 93% surge in WINREVAIR revenue. The company also saw double-digit growth in Gardasil and Welireg, helping to offset declines in legacy products facing generic competition. Despite the strong quarterly performance, management issued a cautionary outlook regarding 2027, forecasting over $2 billion in revenue headwinds due to patent expirations for BRIDION, Adempas, and Januvia. To counter these long-term challenges, Merck is aggressively investing in R&D and new product launches, raising its 2026 revenue guidance to a range of $66.8 billion to $67.3 billion.
Tickers: $MRK
Topics: animal health earnings report generic competition oncology sales revenue growth